Ευρωπαϊκή Ένωση - Ισπανικά - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - pegfilgrastim - neutropenia - inmunoestimulantes, - reducción en la duración de la neutropenia y la incidencia de neutropenia febril en pacientes adultos tratados con quimioterapia citotóxica para la malignidad (con la excepción de crónica mieloide leucemia y mielodisplásicos síndromes).

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - pegfilgrastim - neutropenia - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Ευρωπαϊκή Ένωση - Λιθουανικά - EMA (European Medicines Agency)

hexal ag - filgrastimas - neutropenia; hematopoietic stem cell transplantation; cancer - immunostimulants, - sumažinti trukmė neutropenia ir sergamumas febrilines neutropenia pacientai, gydomi nustatyta citotoksinės chemoterapijos dėl piktybinių navikų (išskyrus lėtinės mieloidinės leukemijos ir mielodisplazinio sindromai) ir sumažinti trukmė neutropenia pacientams, kuriems atliekama myeloablative terapija po kaulų čiulpų transplantacijos laikoma padidintos rizikos ilgą sunkus neutropenia. filgrastimo saugumas ir veiksmingumas yra panašus suaugusiems ir vaikams, kurie gauna citotoksinę chemoterapiją. mobilizacijos periferinio kraujo kamieninių ląstelių (pbpcs). vaikams ir suaugusiems su sunkia įgimta, ciklinis, arba idiopatinė neutropenia su absoliutus neutrofilų skaičius (ans) ≤ 0. 5 x 109/l, ir istorija, sunkių arba pasikartojančių infekcijų, ilgalaikio administracija filgrastim yra nurodyta, padidinti neutrofilų skaičius ir, siekiant sumažinti sergamumą ir trukmė infekcija susijusių renginių. gydymo patvarios neutropenia (anc ≤ 0. 5 x 109/l), ir istorija, sunkių arba pasikartojančių infekcijų, ilgalaikio administracija filgrastim yra nurodyta, padidinti neutrofilų skaičius ir, siekiant sumažinti sergamumą ir trukmė infekcija susijusių renginių. pacientams, kuriems yra pažengusios Živ infekcija, siekiant sumažinti rizikos bakterinės infekcijos, kai kitos gydymo galimybės yra netinkamas.

Μολδαβία - Ρουμανικά - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

farmina srl Îcs - filgrastimum - soluţie injectabilă în seringă preumplută - 300 mcg/0,5 ml

Μολδαβία - Ρουμανικά - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

farmina srl Îcs - filgrastimum - soluţie injectabilă/perfuzabilă - 300 mcg/ml

Βραζιλία - Πορτογαλικά - ANVISA (Agência Nacional de Vigilância Sanitária)

aché laboratórios farmacêuticos s.a - filgrastim - outros produtos que atuam no sangue e hematopoiese

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

sandoz inc. - filgrastim (unii: pvi5m0m1gw) (filgrastim - unii:pvi5m0m1gw) - filgrastim, license holder unspecified 300 ug in 0.5 ml - zarxio is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see clinical studies ( 14.1 )] . zarxio is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (aml) [see clinical studies ( 14.2)] . zarxio is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation [see clinical studies (14.3)]. zarxio is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [see clinical studies (14.4)] . zarxio is indicated for chronic administration t

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

amgen inc - filgrastim (unii: pvi5m0m1gw) (filgrastim - unii:pvi5m0m1gw) - filgrastim 300 ug in 1 ml - neupogen is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see clinical studies (14.1)] . neupogen is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (aml) [see clinical studies (14.2)] . neupogen is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation [see clinical studies (14.3)] . neupogen is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [see clinical studies (14.4)] . neupogen is indicated for chronic administ

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - pegfilgrastim - Ουδετεροπενία - Ανοσοδιεγερτικά, - Μείωση της διάρκειας της ουδετεροπενίας και τη συχνότητα της εμπύρετης ουδετεροπενίας σε ενήλικες ασθενείς που έλαβαν θεραπεία με κυτταροτοξική χημειοθεραπεία για κακοήθεια (με εξαίρεση τα χρόνια μυελογενή λευχαιμία και μυελοδυσπλαστικά σύνδρομα).

Βέλγιο - Ολλανδικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amgen europe b.v. - filgrastim r-met hug-csf - eq. filgrastim 30 10*6 ie - oplossing voor injectie - 0.3 mg/ml - filgrastim r-met hug-csf - filgrastim